PANCREATIC CANCER METASTATIC

This study tests a combination of three drugs (regorafenib, toripalimab, and albumin-bound paclitaxel) as a third-line treatment for people with advanced pancreatic cancer that has spread or cannot be removed. The goal is to see if this mix can slow tumor growth and improve survi…

This early-phase study tests whether adding the cholesterol-lowering drug pitavastatin to standard chemotherapy (gemcitabine and nab-paclitaxel) can help control advanced pancreatic cancer that cannot be removed by surgery. About 18 adults whose cancer has not worsened on initial…

This study tests a new drug called daraxonrasib, which targets a common cancer-driving protein (RAS). It is given alone or with standard chemotherapy to people with metastatic pancreatic cancer that has spread. The goal is to see if the new drug helps people live longer or slows …

This program provides the experimental drug daraxonrasib to adults with advanced pancreatic cancer that has spread and worsened after prior treatments. It is for patients who have no good standard options and cannot join a daraxonrasib clinical trial. The goal is to offer a poten…

This study tests a new treatment called EBNK-001, which uses donor immune cells (natural killer cells) to fight advanced solid tumors. About 83 adults with cancers like lung, breast, or colorectal cancer that have not responded to standard treatments will receive these cells alon…

This study tests a new drug called TNG462, given with other cancer medicines, for people with pancreatic or lung cancer that has a specific genetic change (MTAP loss). The goal is to find safe doses and see if the combination shrinks tumors. About 183 adults with advanced cancer …

This study tests a new chemotherapy combination (paclitaxel polymeric micelles plus gemcitabine) against the current standard treatment for metastatic pancreatic cancer. About 416 adults who have not had prior treatment for their advanced cancer will take part. The goal is to see…

This study tests whether adding the experimental drug atebimetinib to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 510 adults who have not had prior treatment will be randomly assigned to receive either the new combination or standard ch…

This study tests whether adding a new type of targeted nanocell therapy to standard chemotherapy can help people with metastatic pancreatic cancer live longer. The nanocells are designed to deliver a powerful drug directly to cancer cells while also boosting the immune system. Ab…

This study tests whether adding acupuncture to standard anti-nausea medicine works better than medicine alone for people with nausea caused by chemotherapy. About 90 adults with breast, prostate, lung, gynecologic, colorectal, or metastatic pancreatic cancer will be split into tw…